Ypsomed Holding AG · SIX:YPSN
Ypsomed — H1 2022/23 Earnings Presentation
36 slides from Ypsomed's earnings presentation, Nov 16, 2022
Slide 1: Ypsomed Half-Year Results 2022/23
Ypsomed Half-Year Results 2022/23 Strong rise in profitability Webcast, 16 November 2022 PUBLIC
Slide 2: Important information
Important information The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information o
Slide 3: Making selfcare simpler and easier
Making selfcare simpler and easier Improved therapy outcomes for chronic conditions 3 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 4: Making selfcare simpler and easier
Making selfcare simpler and easier Improved therapy outcomes for chronic conditions 4 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 5: Solutions for healthcare's biggest challenge
Solutions for healthcare’s biggest challenge Ypsomed’s underlying growth fundamentals are unchanged Selfcare Improving quality of life, therapy adherence and enabling affordable healthcare systems Biologics Most new-generation drugs with complex active pharmaceutical ingredients have to be injec
Slide 6: Our purpose is a commitment to society
Our purpose is a commitment to society Supporting our ambitions Our products are vital for people with chronic conditions, – resulting in a recurring business model and – being not as dependent on macro-economic cycles We accelerate investments to meet demand With more innovation to come, we w
Slide 7: Recent strategic highlights
Recent strategic highlights Innovation & Digital Health Successful launch of AID with CamDiab, Abbott FSL 3 coming soon Partnership with Sidekick with focus on fast access to Digital Health Access & Expansion Introducing new large volume autoinjector for volumes up to 5.5 ml 16 new project o
Slide 8: Turnover growth of 10% for the Ypsomed Group
Turnover growth of 10 % for the Ypsomed Group Growth of 13 % in constant currency 8 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 9: Delivery Systems strong revenue driver
Delivery Systems strong revenue driver Sales in Ypsomed Delivery Systems (YDS) segment rose again strongly by 21.5 % to CHF 143.7 million In Ypsomed Diabetes Care (YDC) segment, sales declined slightly by 3.4 % to CHF 92.0 million (around CHF 98 million and 3 % growth in constant currency) Sal
Slide 10: Turnover growth of 21.5% in Delivery Systems
Turnover growth of 21.5 % in Delivery Systems 26% sales growth in Injection Systems Strong sales growth of +25.6 % for Injection Systems year-on-year Main contributor to this growth are reusable pens and our autoinjector YpsoMate® 2.25 Contribution to sales from Contract Manufacturing increase
Slide 11: Ypsomed Delivery System (YDS)
Ypsomed Delivery System (YDS) Recurring business model Growth in both established and new products No slow down in acquisition, again 16 new projects with existing and new customers closed, supporting future growth Strong performance in project business based on our large pipeline Platform
Slide 12: Slight decline in turnover in Diabetes Care
Slight decline in turnover in Diabetes Care 32% growth commercial sales YpsoPump® Commercial sales for YpsoPump® increased by 31.8 % (up +40 % in constant currency) Pen needles sales up 12.3 % Lower revenues from development services for pump partners Revenues of test strips declined by 14.0
Slide 13: Ypsomed Diabetes Care (YDC)
Ypsomed Diabetes Care (YDC) Strong uptake in the roll-out of the mylife™ Loop™ AID offering New pump starts already over 1000 per month But up to three months delayed financial recognition due to common reimbursement procedures Launch of worldwide first AID with Abbott Freestyle Libre 3 befo
Slide 14: Over 1000 new YpsoPump starts per month achieved
Over 1 000 new YpsoPump® starts per month achieved 14 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 15: Rollout roadmap mylife CamAPS FX Android
Rollout roadmap mylife™ CamAPS FX Android 15 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 16: Sales performance YDC year-on-year
Sales performance YDC year-on-year Breakdown to Product Areas YDC core-business (excluding DiaExpert and development services) grew at +13.4 % 16 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 17: Divesting DiaExpert
Divesting DiaExpert Focus on own products DiaExpert is an established diabetes specialist and mail-order company in Germany Supplying a wide range of medical devices and over-the-counter products important for everyday life with diabetes Belongs to Ypsomed for over 30 years 180 employees S
Slide 18: Focus on our integrated approach with our own products
Focus on our integrated approach with our own products Leveraging profitability 18 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 19: Investments supporting future growth
Investments supporting future growth CHF 55 million investments in fixed assets Investments in autoinjectors and UnoPen™ Assembly lines, printing systems, injection moulding machines and tools – CHF 30 million in Schwerin – CHF 20 million in Switzerland 19 | Ypsomed Holding AG | Half-Year Resu
Slide 20: Creating 124 new jobs in 6 months
Creating 124 new jobs in 6 months 45 of them in Switzerland 20 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 21: EBIT increased significantly
EBIT increased significantly Development year-on-year 21 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 22: Confirming Outlook
Confirming Outlook For the financial year 2022/23, Ypsomed expects sales growth of the continued operations in the range of the previous financial year. At the EBIT level, we confirm growth of at least 50%, taking into account the negative effects from inflation, higher energy cost and the announc
Slide 23: Innovation & Digital Health
Innovation & Digital Health We invest above average in research and develop- ment. When developing new solutions, the focus is on added value for those affected, the customers and society. PUBLIC
Slide 24: Advanced, modular offering in insulin pump therapy
Advanced, modular offering in insulin pump therapy Successful launch of mylife™ Loop™, our AID offering Highly adaptive algorithm, Smartphone control and easy to use Available for all ages and pregnancy, reducing the mental burden for families Launching the worldwide first AID system compati
Slide 25: Freedom of choice with mylife Loop
Freedom of choice with mylife™ Loop™ 25 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 26: Digital Health is evolving to evidence-based solutions
In both YDC and YDS, Digital Health is evolving to evidence-based solutions Shift from product differentiation to improving therapy outcomes Evidence-based and clinically validated Increase of therapy efficacy through combination of traditional treatments with digital therapeutics (DTx) Enab
Slide 27: Entering a strategic collaboration with Sidekick Health
Entering a strategic collaboration with Sidekick Health Gamified and evidence-based digital therapeutics platform 27 | Ypsomed Holding AG | Half-Year Results 2022/23 PUBLIC
Slide 28: Neurobehavioral injection module
Neurobehavioral injection module Integrated into Sidekick’s digital therapeutics platform Developing a device-digital module to support patients with self-injections Digital and in-person coaching to increase rate of successful injections Reminders to increase adherence Psychological support
Slide 29: Digital therapeutics offer significant added value
Digital therapeutics offer significant added value Across a wide spectrum of chronic conditions Timely identification of toxicities and adverse events Oncology Improved overall survival for patients with symptom reporting Reduced cancer-related fatigue and improved quality of life Aapro, M., e
Slide 30: Access & Expansion
Access & Expansion We improve medical care worldwide. To make life easier for those affected, we want to serve the widest possible range of disease areas. PUBLIC
Slide 31: Current and potential future disease areas served
Current and potential future disease areas served Pens Auto- and patch-injectors Diabetes Asthma Osteoporosis Migraine Growth disorders Multiple sclerosis Fertility Sexual dysfunction Parkinson Rheumatoid arthritis Rheumatoid arthritis Psoriasis Bullous pemphigoid Dermati
Slide 32: YpsoMate 5.5 large volume autoinjector
YpsoMate® 5.5 – the 5.5 ml large volume autoinjector Unlocking new applications for handheld autoinjectors Latest addition to the growing YpsoMate® family of devices Based on the established technology of the YpsoMate® 2.25 Pro Larger dosing volumes can reduce the number of injections required
Slide 33: Platforms & Operational Excellence
Platforms & Operational Excellence With our platform approach and scalable capacities, we are able to provide products quickly and reliably. We operate according to the principles of lean manage- ment and highly automated processes to expand our cost leadership. PUBLIC
Slide 34: Statement on the energy supply
Statement on the energy supply Ypsomed does not require natural gas in operations, and only minimal for heating Within the scope of business continuity, a dedicated Energy Task Force and a defined action plan for power management are in place Numerous measures have been identified to save elec
Slide 35: Signing for a new manufacturing site in China
Signing for a new manufacturing site in China Changzhou National High-Tech Industry Development District China is a rapidly growing market for Ypsomed, in particular for UnoPen™ To foster long-term partnerships and to eliminate shipping, we set up a local manufacturing site: − 15’000 m2 land, op
Slide 36: Thank you.
PLT at ee om m2 L] a Bos | 2 tt || ee ead PUBLIC